Dataset Information

Engineering platelets as targeted protein degraders

ABSTRACT: We covalently tethered the POI ligand to heat shock protein 90 (HSP90) within platelets through ligand-directed covalent labeling method mediated by the N-acyl-N-alkyl sulfonamide (NASA) linker. These proteolytic platelets, termed DePLT, could selectively accumulate at wound-associated disease sites and then potently degrade the POI by repurposing the critical role of molecular chaperones in protein processing.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): 4t1 Cell

SUBMITTER: Yu Chen

LAB HEAD: Quanyin Hu

PROVIDER: PXD055866 | Pride | 2025-12-08

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20230808_DDA_B1_1_1_1_2237_uncalibrated.mzML	Mzml
	20230808_DDA_B1_2_1_1_2249_uncalibrated.mzML	Mzml
	20230808_DDA_B2_1_1_1_2239_uncalibrated.mzML	Mzml
	20230808_DDA_B2_2_1_1_2251_uncalibrated.mzML	Mzml
	20230808_DDA_B3_1_1_1_2241_uncalibrated.mzML	Mzml

Items per page:

1 - 5 of 14

Publications

Engineered platelets as targeted protein degraders and application to breast cancer models.

Chen Yu Y Pal Samira S Li Wen W Liu Fengyuan F Yuan Sichen S Hu Quanyin Q

Nature biotechnology 20241203 11

Clinical application of chimeric molecules for targeted protein degradation has been limited by unfavorable drug-like properties and biosafety concerns arising from nonspecific biodistribution after systemic administration. Here we develop a method to engineer platelets for degradation of either intracellular or extracellular proteins of interest (POIs) in vivo by covalently labeling heat shock protein 90 (HSP90) in platelets with a POI ligand. The degrader platelets (DePLTs) target wound areas ...[more]

PMID: 39627511

Similar Datasets

Project description:Mesenchymal stromal cells (MSCs) are promising candidates for innovative cell therapeutic applications. For clinical scale manufacturing regulatory agencies recommend to replace fetal bovine serum (FBS) commonly used in MSC expansion media as soon as equivalent alternative supplements are available. We already demonstrated that pooled blood group AB human serum (HS) and thrombin-activated platelet releasate plasma (tPRP) support the expansion of multipotent adipose tissue-derived MSCs (ASCs). Slight differences in size, growth pattern and adhesion prompted us to investigate the level of equivalence by compiling the transcriptional profiles of ASCs cultivated in these supplements. A whole genome gene expression analysis was performed and data verified by PCR and protein analyses. Microarray-based screening of 34,039 genes revealed 102 genes differentially expressed in ASCs cultured with FBS compared to HS or tPRP supplements. A significantly higher expression in FBS cultures was found for 90 genes (fold change .2). Only 12 of the 102 genes showed a lower expression in FBS compared to HS or tPRP cultures (fold change .0.5). Differences between cells cultivated in HS and tPRP were hardly evident. Supporting previous observations of reduced adhesion of cells cultivated in the human alternatives we detected a number of adhesion and extracellular matrix associated molecules expressed at lower levels in ASCs cultivated with human supplements. Confirmative assays analysing transcript or protein expression with selected genes supported these results. Likewise a number of mesodermal differentiation associated genes were higher expressed in cells grown in FBS. Quantifying adipogenic and osteogenic differentiation lacked to demonstrate a clear correlation to the supplement due to donor-sepcific variances. Our results emphasize the necessity of comparability studies as they indicate that FBS induces a culture adaptation exceeding that of ex vivo culture in human supplements and thus may contribute to the therapeutic potential. Microarray hybridizations (Agilent: Whole Human Genome Oligo Microarray; 41k unique probe) were carried out with 5 µg Cy3 labeled cRNA and 5 µg Cy5 labeled cRNA, both prepared from each sample.